SC Filed 2024-04-01 Event — SEC 0001193125-24-083703 →

Fairmount Funds Management LLC → Cogent Biosciences, Inc. COGT

Stake: — Shares: —

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

2 13D/G filings on this issuer

1 other filing besides this one

Filer Track Record

7 filings by this filer

6 other filings in the data moat

Short Interest · settle 2026-03-31

DTC 7.10

17,425,998 shares short · +11.7% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

2 holders · $29.47M

Duquesne Family OfficePoint72 Asset Mgmt

Other 13D/G Filings on Cogent Biosciences, Inc.

Filed	Form	Filer	Stake	Shares
2026-01-22	SCHEDULE	Fairmount Funds Management LLC	9.90%	16,261,918	view →

Other Filings by Fairmount Funds Management LLC

Filed	Form	Issuer	Stake	Shares
2026-01-22	SCHEDULE	Apogee Therapeutics, Inc. APGE	9.99%	6,047,027	view →
2026-01-22	SCHEDULE	Cogent Biosciences, Inc. COGT	9.90%	16,261,918	view →
2025-03-10	SCHEDULE	Oruka Therapeutics, Inc. ORKA	19.99%	8,511,824	view →
2024-04-01	SC	Dianthus Therapeutics, Inc. /DE/ DNTH	—	—	view →
2024-04-01	SC	Viridian Therapeutics, Inc.\DE VRDN	—	—	view →
2024-04-01	SC	Apogee Therapeutics, Inc. APGE	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. $1,500/mo. Pilots welcome.

Request a pilot →